Mecapegfilgrastim
- Generic Name
- Mecapegfilgrastim
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于成年非髓性恶性肿瘤患者在接受容易引起发热性中性粒细胞减少症的骨髓抑制性抗癌药物治疗时，降低以发热性中性粒细胞减少症为表现的感染发生率。本品不用于造血干细胞移植的外周血祖细胞的动员。
- Associated Conditions
- -
- Associated Therapies
- -
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 70
- Registration Number
- NCT06684158
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-04-12
- Target Recruit Count
- 132
- Registration Number
- NCT05463601
- Locations
- 🇨🇳
中山大学中山纪念医院, Guangzhou, Guangdong, China
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2019-11-21
- Target Recruit Count
- 93
- Registration Number
- NCT04171986
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath